Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex
2009
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Complete Replication of Hepatitis C Virus in Cell Culture
2005 StandoutScienceNobel
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
2007 StandoutNobel
A drug-controllable tag for visualizing newly synthesized proteins in cells and whole animals
2008 StandoutNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism
2009 StandoutNobel
The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication
2009
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Pan-Genotype Hepatitis E Virus Replication in Stem Cell–Derived Hepatocellular Systems
2017 StandoutNobel
Challenges and successes in developing new therapies for hepatitis C
2005 Nature
Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins
2014
Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro
2006
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
2004
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Completion of the entire hepatitis C virus life cycle in genetically humanized mice
2013 StandoutNatureNobel
Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir
2007
DNA recognition by an RNA-guided bacterial Argonaute
2017 StandoutNobel
The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice
2005
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures
2010 StandoutNobel
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells
2010 StandoutNobel
Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics
2009
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)
2011
Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti‐hepatitis C virus strategy
2007
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor
2012
Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents
2011
Characterization of resistance mutations against HCV ketoamide protease inhibitors
2008
The role of resistance in HCV treatment
2012
What are the pros and cons of the use of host-targeted agents against hepatitis C?
2014
Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology
2007
Metazoan MicroRNAs
2018 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
A Major Determinant of Cyclophilin Dependence and Cyclosporine Susceptibility of Hepatitis C Virus Identified by a Genetic Approach
2010
Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A
2010
The Serine Protease Domain of Hepatitis C Viral NS3 Activates RNA Helicase Activity by Promoting the Binding of RNA Substrate
2007
Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo
2011
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus
2010
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors
2010
Cyclophilin inhibitors in hepatitis C viral infection
2007
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
2015 StandoutNobel
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
2011
DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
2010
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice
2010
Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer
2017 StandoutNobel
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
2009
Hepatitis C Virus NS5B and Host Cyclophilin A Share a Common Binding Site on NS5A
2012
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A
2010
Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B
2007
Hepatitis C Virus Entry
2007 StandoutNobel
Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor
2005
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study
2006
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Host sphingolipid biosynthesis as a target for hepatitis C virus therapy
2005
Domain 3 of NS5A Protein from the Hepatitis C Virus Has Intrinsic α-Helical Propensity and Is a Substrate of Cyclophilin A
2011
Inhibition of HCV Replication by Cyclophilin Antagonists Is Linked to Replication Fitness and Occurs by Inhibition of Membranous Web Formation
2014
Therapy of Hepatitis C: From Empiricism to Eradication
2006
Curing a viral infection by targeting the host: The example of cyclophilin inhibitors
2013
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
2006
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Replication of hepatitis C virus
2007 StandoutNobel
Telaprevir and pegylated interferon–alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
2007
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro†
2006
Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro
2007
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells
2004
Expression of MicroRNA miR-122 Facilitates an Efficient Replication in Nonhepatic Cells upon Infection with Hepatitis C Virus
2012
Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice
2015 StandoutNobel
Covalent Modifiers: An Orthogonal Approach to Drug Design
2009
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro
2008
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
Development of an Intergenotypic Hepatitis C Virus (HCV) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS3 Protease Genes from HCV Genotypes 1 to 6
2010
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
2010
Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors
2008
Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus
2007 StandoutNobel
Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System
2007
Review HCV Antiviral Resistance: The Impact of in vitro Studies on the Development of Antiviral Agents Targeting the Viral NS5B Polymerase
2005
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Development of a Cell-Based Hepatitis C Virus Infection Fluorescent Resonance Energy Transfer Assay for High-Throughput Antiviral Compound Screening
2009
Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro
2008
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle
2010 StandoutNobel
Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry
2006 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796
2008
SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA ReplicationIn Vitro
2009
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
Evaluation of Phosphatidylinositol-4-Kinase IIIα as a Hepatitis C Virus Drug Target
2012
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
2011
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro
2005
Works of Sue Ma being referenced
In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
2005
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
2004
Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance
2008
[608] NIM811, A CYCLOPHILIN INHIBITOR, AND NM107, AN HCV POLYMERASE INHIBITOR, SYNERGISTICALLY INHIBITS HCV REPLICATION AND SUPPRESSES THE EMERGENCE OF RESISTANCE IN VITRO
2007
NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon
2006
Mechanism of Resistance of Hepatitis C Virus Replicons to Structurally Distinct Cyclophilin Inhibitors
2010